Pharmacogenetic testing for patients with drug reactions or therapy failure
Official title: Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
Run by University Hospital, Basel, Switzerland · NCT04154553 · Data updated 2026-11-12
This study is trying to see if testing patients' genes can help find safer and more effective medications for those who have had bad reactions or who aren't getting better with their current treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Status | Recruiting |
| Started | October 15, 2019 |
| Main results expected | August 2026 |
| Study ends | August 2026 |
| Registry record updated | May 14, 2025 |
| Trial ID | NCT04154553 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients starting new medications or those experiencing adverse drug reactions or therapy failures linked to medications with known pharmacogenetic associations.
✕Probably not a fit
Patients who do not have a sufficient understanding of German or cannot visit the study pharmacy in person may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on the impact of genetic factors on drug efficacy and safety by compiling case reports where pharmacogenetic testing has been utilized. It collects health-related data from patients experiencing therapy failure or adverse drug reactions and supplements this with pharmacogenetic testing in a community pharmacy setting. The goal is to develop a reliable standard procedure for pharmacogenetic testing based on the compiled cases and additional literature parameters affecting drug efficacy and safety.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective medication management for patients, reducing adverse drug reactions and therapy failures.
How similar studies have gone: Other studies have shown promising results with pharmacogenetic testing, indicating its potential effectiveness in improving patient outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * New medication with known PGx association (preemptive) * Current medication with observation of adverse drug reactions probably linked to drugs with known PGx association (reactive) * Current medication with observation of therapy failure probably linked to drugs with known PGx association (reactive) * Current and/or new medication and a family history of adverse drug reactions/therapy failure probably linked to drugs with known PGx association * Signed informed consent; for patients \< 14 years, the legal representative needs to sign the informed consent Exclusion Criteria: * Insufficient German knowledge * Not able to personally visit to the study pharmacy
Where it's running
-
Department of Pharmaceutical Sciences, University Basel
Basel, Switzerland Recruiting
Study contacts
- Principal investigator: Samuel Allemann, Prof. Dr. — Pharmaceutical Care Research Group; Department of Pharmaceutical Sciences, University Basel
- Study coordinator: Samuel Allemann, Prof. Dr.
- Email: s.allemann@unibas.ch
- Phone: +41 61 207 61 76
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating adverse drug reactions in patients taking multiple medications
This study is testing how taking multiple medications affects side effects in at-risk patients to help doctors make better treatment choices.
-
Predicting bowel leaks after colorectal surgery with a computer model and surgeon input
This study tests a computer model that predicts anastomotic leaks after colorectal surgery, and sees if adding surgeons’ intuition improves the predictions.
-
Active surveillance after immunotherapy for MMR-deficient colorectal and GI cancers
This study looks at whether some patients with non-metastatic, MMR-deficient or MSI-H colorectal cancers can skip surgery after a strong response to immunotherapy.
-
PCI Registry at University Hospital Basel for Complex Coronary Procedures
This registry collects real-world data from adults undergoing percutaneous coronary interventions at University Hospital Basel to see how different treatments like drug-eluting stents, drug-coated balloons, and bioresorbable scaffolds perform in diverse patients.
-
Severe Complications During VT/PVC Ablation
This study looks at real-world cases to see what severe complications occur during VT or PVC ablations and how patients are managed afterward.
-
Visioning III: Five-year follow-up for MRI-based prostate cancer screening
This study tests a repeat MRI-based screening approach for men who previously had no cancer signs, to see if a negative bpMRI reliably predicts no significant cancer for at least five years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.